These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15708540)

  • 1. Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management.
    Portincasa P; Grattagliano I; Palmieri VO; Palasciano G
    Clin Biochem; 2005 Mar; 38(3):203-17. PubMed ID: 15708540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging problem of nonalcoholic steatohepatitis (NASH).
    Portincasa P; Grattagliano I; Palmieri VO; Palasciano G
    Rom J Gastroenterol; 2005 Mar; 14(1):43-51. PubMed ID: 15800693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis.
    Nocito A; Dahm F; Jochum W; Jang JH; Georgiev P; Bader M; Renner EL; Clavien PA
    Gastroenterology; 2007 Aug; 133(2):608-18. PubMed ID: 17681180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Nonalcoholic steatohepatitis: pathogenesis and treatment].
    Park SH
    Korean J Hepatol; 2008 Mar; 14(1):12-27. PubMed ID: 18367854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of nonalcoholic steatohepatitis (NASH).
    Ma X; Li Z
    Chin J Dig Dis; 2006; 7(1):7-11. PubMed ID: 16412031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis.
    Wieckowska A; Papouchado BG; Li Z; Lopez R; Zein NN; Feldstein AE
    Am J Gastroenterol; 2008 Jun; 103(6):1372-9. PubMed ID: 18510618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and therapy of nonalcoholic steatohepatitis.
    Torres DM; Harrison SA
    Gastroenterology; 2008 May; 134(6):1682-98. PubMed ID: 18471547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [NASH -- nonalcoholic steatohepatitis].
    Blechacz B; Stremmel W
    Z Gastroenterol; 2003 Jan; 41(1):77-90. PubMed ID: 12541180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathology of nonalcoholic fatty liver disease.
    Yeh MM; Brunt EM
    Am J Clin Pathol; 2007 Nov; 128(5):837-47. PubMed ID: 17951208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new?
    Ariz U; Mato JM; Lu SC; Martínez Chantar ML
    Methods Mol Biol; 2010; 593():109-36. PubMed ID: 19957147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormalities of lipid metabolism in nonalcoholic fatty liver disease.
    Cheung O; Sanyal AJ
    Semin Liver Dis; 2008 Nov; 28(4):351-9. PubMed ID: 18956291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease in type 2 diabetes mellitus.
    Cusi K
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):141-9. PubMed ID: 19262374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH.
    Koike K; Moriya K
    J Gastroenterol; 2005 Apr; 40(4):329-36. PubMed ID: 15868369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future.
    Wieckowska A; McCullough AJ; Feldstein AE
    Hepatology; 2007 Aug; 46(2):582-9. PubMed ID: 17661414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harrison SA; Neuschwander-Tetri BA
    Clin Liver Dis; 2004 Nov; 8(4):861-79, ix. PubMed ID: 15464659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment.
    Carter-Kent C; Zein NN; Feldstein AE
    Am J Gastroenterol; 2008 Apr; 103(4):1036-42. PubMed ID: 18177455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
    Ito S; Yukawa T; Uetake S; Yamauchi M
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in nonalcoholic fatty liver disease.
    Cheung O; Sanyal AJ
    Curr Opin Gastroenterol; 2010 May; 26(3):202-8. PubMed ID: 20168226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The natural history and risk factors for progression of non-alcoholic fatty liver disease and steatohepatitis.
    Miele L; Forgione A; Hernandez AP; Gabrieli ML; Vero V; Di Rocco P; Greco AV; Gasbarrini G; Gasbarrini A; Grieco A
    Eur Rev Med Pharmacol Sci; 2005; 9(5):273-7. PubMed ID: 16231589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.